Jaguar nabs Novartis pro for board seat; Zoetis teams with Trophogen on bovine fertility drug; OncoSec to test immunotherapy in pet dogs treated at UC Davis;

> Jaguar Animal Health ($JAGX) has named Novartis ($NVS) Animal Health veteran Folkert Kamphuis to its board of directors. Release

> Zoetis ($ZTS) has acquired an exclusive license from Maryland-based biotech company Trophogen to develop a recombinant modified bovine Follicle-Stimulating Hormone (rbFSH) analog for use in beef and dairy cows. Release

> OncoSec Medical is collaborating with the University of California, Davis, School of Veterinary Medicine to test its immunotherapy treatment, ImmunoPulse IL-12, in dogs with soft tissue sarcoma. Release

> Market research firm Packaged Facts has released a new report predicting the U.S. market for pet medications will maintain a compound annual growth rate of 5% and will hit $10.2 billion in 2018. Release

> Nexvet Biopharma ($NVET) has formed a partnership with Fujifilm Diosynth Biotechnologies for the manufacturing of its two most advanced drug candidates, NV-01 and NV-02 to treat pain in pets. Release

> India's Hester Bioscience reported that its net sales grew 30% and its net profit 45% in fiscal 2014. Release (PDF)

> Florida-based Nuovo Biologics has partnered with Auburn University's Research Initiative in Cancer to develop new therapies for canine malignant melanoma. Release

> Ainsworth Pet Nutrition has recalled 5 varieties of Rachael Ray Nutrish wet cat food due to potentially elevated levels of vitamin D. Release

Suggested Articles

Pfizer spinoff Zoetis met Q2 expectations and brightened its full-year forecast, but it's looking to M&A to drive further growth.

Fresenius’ new CEO has pulled off a dealmaking double play, committing more than $5.4 billion to expand its reach in both sterile generics and in biosimilars.

Bayer’s pharma products have been growing lickety-split, and its 2016 numbers show just how—and how much. But with the big Monsanto merger top of mind at Bayer…